In Another Pfizer Fire Sale, VC-Backed Conatus Acquires Idun's Idle Assets
This article was originally published in The Pink Sheet Daily
Launched in 2006 by Idun's former management team, San Diego startup Conatus buys back a familiar property at a rock-bottom price.
You may also be interested in...
Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity
ViiV Healthcare will market the two companies' combined portfolio of 10 HIV drugs while also taking over a 17-compound R&D operation.
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.